Although Pfizer (NYSE:PFE) has yet to receive emergency use authorization for its Paxlovid COVID-19 therapy, it plans to manufacture 80 million courses of the drug by the end of 2022. Pfizer had initially planned on making 50 million courses of Paxlovid (PF-07321332/ritonavir) in the same time frame.
An interim analysis of the Phase 2/3 EPIC-HR study found the drug to be 89% effective at reducing hospitalization or death. Pfizer announced the launch of a Phase 1 study of PF-07321332 in March.
Pfizer has inked a $5.29 billion Paxlovid deal with the U.S. government.
One course of oral Paxlovid therapy would consist of two daily 150-mg doses for five days.
Meanwhile, molnupiravir, the antiviral from Merck (NYSE:MRK) and Ridgeback Biotherapeutics, has lost some of its luster. New data suggests the drug led to an absolute risk reduction against hospitalization or death of 3% compared to placebo. Furthermore, the drug led to a relative risk reduction of 30%. Earlier data suggested that the drug offered a 50% relative risk reduction.
FDA advisors will meet tomorrow to discuss whether the benefits of molnupiravir outweigh the risks.
Pfizer announced in mid-November that it had filed paperwork with the FDA for emergency use authorization of Paxlovid. The company is also seeking market authorization for the drug candidate in the European Union.
Tell Us What You Think!